News

Dynasil Corporation of America ("Dynasil" or the "Company"), a leading developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for homeland security, medical and industrial markets, today announces that it has appointed Militram Futuristic Technologies of Israel to pursue the growing demand in Israel’s industrial, commercial and military segments.

Printed in Photonics News Daily

Dynasil, a global supplier of fused silica, coatings, components, and scintillation and detection solutions, is focused on cutting-edge research and commercial product development in photonics. With eight locations across two continents, it serves customers in more than 60 countries. CEO Peter Sulick shares operational highlights and what lies ahead for the industry and Dynasil.

Dynasil Corporation of America ("Dynasil" or the "Company") (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced the appointment of Nirmal Parikh, a 20-year industry expert to the position of Vice President, Marketing.

Presentation given at the Dynasil Corporation of America Annual Meeting on February 22, 2018. Presenation by Peter Sulick, CEO and Chairman Dynasil Corporation, Linda Zuckerman Ph.D. CEO Xcede Technologies, Kanai Shah Ph.D., President RMD, and Gary Bishop Ph.D. V.P. of Photonics Dynasil Corporation.

Newton, Mass., January 17, 2018 – Dynasil Corporation of America (NASDAQ: DYSL) today announced its subsidiaries EMF Corporation and Optometrics Corporation have completed their development of the first in a series of Infrared High Efficiency Anti-Reflective (HEAR) thin film coatings for the eight to twelve micron spectral region.

Newton, MA. Jan 11, 2018 – The Xcede Patch clinical trial dossier was submitted today to the Medical Ethical Review Committee (MREC) Universitair Medisch Centrum Groningen (Netherlands), in anticipation of a first-in-human clinical trial. The clinical trial, which outlines the treatment of up to 30 patients undergoing various types of liver resection, will take place at two major liver surgery centers in The Netherlands. Subject to the MREC approvals, the Company anticipates that patients will be treated with the Xcede Patch in the Netherlands in early 2018.

Dynasil hosted its annual meeting on February 23rd, 2017 in Watertown, MA on the campus of its RMD subsidiary. The meeting included presentations by President and CEO, Peter Sulick, President of RMD, Dr. Kanai Shah and CEO of Xcede, Dr. Linda Zuckerman.

Newton, MA, February 13, 2017 – Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced earnings attributable to common stockholders of $2.8 million or $0.17 per common share for the first quarter of the 2017 fiscal year, largely as the result of a U.S. income tax benefit resulting from the deconsolidation for tax purposes of Xcede Technologies, Inc., the Company’s tissue sealant technology development joint venture.

Company to Webcast Conference Call Live at 5:00 p.m. ET on February 14

Newton, Mass., February 9, 2017 – Dynasil Corporation of America (NASDAQ: DYSL) plans to release financial results for the fiscal quarter ended December 31, 2016 on Monday, February 13 and management will host a conference call for investors and analysts the following day, February 14, 2017 at 5:00 p.m. ET.

Newton, MA, December 21, 2016 – Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced net income of $0.3 million and $0.04 per common share for the fiscal year ended September 30, 2016 and the filing of its Annual Report on Form 10-K.